Supplementary Table 3. Sensitivity analysis before and after controlling anti-hyperuricemia medication information.

| △UA  (Relative, %) | Incidents / participants | Model 3a | | Model 3b | |
| --- | --- | --- | --- | --- | --- |
| HR (95%CI) | *p value* | HR (95%CI) | *p value* |
| Per 10% increase | 899/23262 | 1.046(1.007,1.086) | 0.021 | 1.046(1.007,1.086) | 0.021 |
| >30% loss | 24/526 | 1.129(0.743,1.715) | 0.570 | 1.130(0.743,1.718) | 0.567 |
| 20-30% loss | 71/1800 | 1.099(0.850,1.421) | 0.470 | 1.100(0.851,1.422) | 0.468 |
| 10-20% loss | 159/4538 | 1.037(0.861,1.250) | 0.699 | 1.038(0.861,1.250) | 0.699 |
| ±10% | 405/11438 | 1.000 | - | 1.000 | - |
| 10-20% gain | 122/2720 | 1.190(0.969,1.461) | 0.098 | 1.190(0.969,1.461) | 0.098 |
| 20-30% gain | 64/1234 | 1.289(0.985,1.687) | 0.064 | 1.289(0.985,1.687) | 0.064 |
| >30% gain | 54/1006 | 1.365(1.018,1.830) | 0.038 | 1.365(1.018,1.830) | 0.038 |
| *p* for trend |  | 0.077 | | 0.077 | |

Model 3a: adjusted for sex, age, education levels, household income, occupation, smoking status, drinking status, exercising status, family history of stroke, serum uric acid, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, and estimated glomerular filtration rate.

Model 3b: adjusted for model 3a plus anti-hyperuricemia medication.

HR, hazard ratio; CI, confidence interval.